273 related articles for article (PubMed ID: 8895007)
1. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
[TBL] [Abstract][Full Text] [Related]
2. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
[TBL] [Abstract][Full Text] [Related]
3. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
[TBL] [Abstract][Full Text] [Related]
4. Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-alpha.
Löhr H; Nagel C; Dienes HP; Simpson B; Michel G; Goergen B; Meyer zum Büschenfelde KH; Gerken G
Hepatology; 1994 Dec; 20(6):1383-9. PubMed ID: 7526999
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of quantitative assay for antibody to hepatitis C virus core in patients treated with interferon.
Yoshimura E; Hayashi J; Kishihara Y; Yamaji K; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1996 Jan; 41(1):155-60. PubMed ID: 8565749
[TBL] [Abstract][Full Text] [Related]
6. Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection.
Urushihara A; Sodeyama T; Matsumoto A; Tanaka E
J Med Virol; 1994 Apr; 42(4):348-56. PubMed ID: 7519250
[TBL] [Abstract][Full Text] [Related]
7. The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon.
Negro F; Abate ML; Mondardini A; Baldi M; Leandro G; Lombardi S; Wolfe L; Ryff JC; Verme G; Brunetto MR
J Viral Hepat; 1995; 2(4):171-4. PubMed ID: 7489343
[TBL] [Abstract][Full Text] [Related]
8. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
[TBL] [Abstract][Full Text] [Related]
9. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome.
Quiroga JA; van Binsbergen J; Wang CY; Pardo M; Navas S; Trines C; Herrero M; Carreño V
Hepatology; 1995 Dec; 22(6):1635-40. PubMed ID: 7489967
[TBL] [Abstract][Full Text] [Related]
11. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
Kakumu S; Aiyama T; Okumura A; Iwata K; Ishikawa T; Yoshioka K
J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
[TBL] [Abstract][Full Text] [Related]
13. HCV replication in mononuclear cells stimulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alpha.
Löhr HF; Goergen B; Meyer zum Büschenfelde KH; Gerken G
J Med Virol; 1995 Aug; 46(4):314-20. PubMed ID: 7595407
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients.
Tabone M; Secreto P; Marini C; Bonardi R; Boero M; Taraglio S; Ercole E; Sallio Bruno F; Pera A
Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):287-91. PubMed ID: 9096432
[TBL] [Abstract][Full Text] [Related]
15. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.
Vandelli C; Renzo F; Braun HB; Tisminetzky S; Albrecht M; De Palma M; Ranzi A; Di Marco G; Stroffolini T; Baralle F; Ventura E; Michel G
J Med Virol; 1999 May; 58(1):26-34. PubMed ID: 10223542
[TBL] [Abstract][Full Text] [Related]
16. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
17. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
[TBL] [Abstract][Full Text] [Related]
18. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
[TBL] [Abstract][Full Text] [Related]
19. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication, and liver disease outcome in chronic hepatitis C.
Quiroga JA; Herrero M; Castillo I; Navas S; Pardo M; Carreño V
J Infect Dis; 1994 Sep; 170(3):669-73. PubMed ID: 7521377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
